

WO 00/09557 A1

---

Job No.: 1505-80958

Translated from Japanese by the Ralph McElroy Translation Company  
910 West Avenue, Austin, Texas 78701 USA

INTERNATIONAL PATENT OFFICE  
WORLD ORGANIZATION FOR INTELLECTUAL PROPERTY

International patent published on  
the basis of the Patent Cooperation Treaty

INTERNATIONAL PUBLICATION NO. WO 00/09557 A1

International Patent Classification<sup>6</sup>:

C 07 K	14/47
C 12 N	15/12
	//5/10
C 12 P	21/02
(C 12 P	21/02
C 12 R	1:91)

International Filing No.:

PCT/JP99/04352

International Filing Date:

August 11, 1999

International Publication Date:

February 24, 2000

Priority

Date:

August 12, 1998

Country:

JP

No.:

Hei 10[1998]-227723

Designated States:

AU, CA, CN, KR, US, European  
patent (AT, BE, CH, CY, DE, DK,  
ES, FI, FR, GB, GR, IE, IT, LU,  
MC, NL, PT, SE)

NOVEL GENE AND PGTH PROTEIN ENCODED THEREBY

Inventors and

Inventors/Applicants (only for US):

Osamu Ohara;  
Takahiro Nagase;  
Nobuo Nomura  
Kazusa DNA Research Institute  
Foundation  
1532-3 Yakuni, Kisarazu-shi,  
Chiba-ken (JP)

Kiyoshi Takayama  
Hitoshi Toyoda;  
Makoto Yoshimoto  
Taisho Pharmaceutical Co., Ltd.  
3-24-1 Takata, Toshima-ku,  
Tokyo-to (JP)

Applicant (for all designated  
states other than US):

Kazusa DNA Research Institute  
Foundation  
1532-3 Yakuni  
Kisarazu-shi, Chiba-ken (JP)

Taisho Pharmaceutical Co., Ltd.  
3-24-1 Takata, Toshima-ku,  
Tokyo-to (JP)

Agent:

Tomizo Kitagawa  
Taisho Seiyaku K.K.  
3-24-1 Takata, Toshima-ku,  
Tokyo-to (JP)

Published

With International Search Report.

## FOR INFORMATION ONLY

Codes for the identification of PCT contract states on the cover sheets of the documents that publish the international applications in accordance with the PCT.

AE	United Arab Emirates	KP	Democratic People's	YU	Yugoslavia
AL	Albania		Republic of Korea	ZA	South Africa
AM	Armenia	KR	South Korea	ZW	Zimbabwe
AT	Austria	KZ	Kazakhstan		
AU	Australia	LC	Saint Lucia		
AZ	Azerbaijan	LI	Liechtenstein		
BA	Bosnia-Herzegovina	LK	Sri Lanka		
BB	Barbados	LR	Liberia		
BE	Belgium	LS	Lesotho		
BF	Burkina Faso	LT	Lithuania		
BG	Bulgaria	LU	Luxembourg		
BJ	Benin	LV	Latvia		
BR	Brazil	MA	Morocco		
BY	Belarus	MC	Monaco		
CA	Canada	MD	Republic of Moldavia		
CF	Central African Republic	MG	Madagascar		
CG	Congo	MK	Macedonia (former Yugoslavian Republic of Macedonia)		
CH	Switzerland				
CI	Côte d'Ivoire	ML	Mali		
CM	Cameroon	MN	Mongolia		
CN	China	MR	Mauritania		
CR	Costa Rica	MW	Malawi		
CU	Cuba	MX	Mexico		
CY	Cyprus	NE	Niger		
CZ	Czech Republic	NL	Netherlands		
DE	Germany	NO	Norway		
DK	Denmark	NZ	New Zealand		
DM	Dominica	PL	Poland		
EE	Estonia	PT	Portugal		
ES	Spain	RO	Romania		
FI	Finland	RU	Russian Federation		
FR	France	SD	Sudan		
GA	Gabon	SE	Sweden		
GB	United Kingdom	SG	Singapore		
GD	Grenada	SI	Slovenia		
GE	Georgia	SK	Slovakia		
GH	Ghana	SL	Sierra Leone		
GM	Gambia	SN	Senegal		
GN	Guinea	SZ	Swaziland		
GR	Greece	TD	Chad		
HR	Croatia	TG	Togo		
HU	Hungary	TJ	Tajikistan		
ID	Indonesia	TM	Turkmenistan		
IE	Ireland	TR	Turkey		
IL	Israel	TT	Trinidad and Tobago		
IN	India	TZ	Tanzania		
IS	Iceland	UA	Ukraine		
IT	Italy	UG	Uganda		
JP	Japan	US	United States of America		
KE	Kenya				
KG	Kyrgyzstan	UZ	Uzbekistan		
		VN	Vietnam		

#### Field of the technology

This invention pertains to a novel PGTH protein of human brain origin having a prostaglandin transport activity and the pgth gene encoding the protein.

#### Prior art

Prostaglandin is a generic name for a series of physiologically active lipids such as prostaglandin E, prostaglandin D, prostaglandin F, prostaglandin I, prostaglandin J, etc. Prostaglandin is a physiologically active substance inside the body strongly related to control of physiological functions such as blood flow rate, sleeping, gastric mucosa protective action, thrombus formation, pregnancy, etc., through specific cell membrane or intranuclear receptors.

Prostaglandin is produced inside cells as a result of eicosapolyenic acids such as arachidonic acid, etc., being cut out by phospholipase A2 from the cell membrane and converted with cyclooxygenase and various prostaglandin synthetic enzymes by responding to various physiological stimuli, and after being released outside the cells, it has autocrine or paracrine effects. On the other hand, liberated prostaglandin is also circulated in the blood flow, taken up by a specific cell, metabolized and so disappears.

A trace amount of prostaglandin shows a strong physiological activity, and consequently, the production of prostaglandin compounds is strictly controlled by controlling the activity of production-related and metabolism-related enzymes.

However, prostaglandin has been reported to be unable to pass through the lipid double layer of the cell membrane by itself. Therefore, as a prostaglandin transport mechanism, the presence of a special protein has been presumed in the process of prostaglandin produced inside a cell exiting it and the process of prostaglandin circulating in the blood flow being taken up into a specific cell.

As a protein involved in the transport mechanism described above, prostaglandin transporter (abbreviated hPGT: human prostaglandin transporter, below) has been reported, but it is not a protein involved in the transport of all prostaglandin compounds, and there are many unclear points. Consequently, it is thought that if a biological molecule other than hPGT involved in the transport mechanism can be elucidated, the biological molecule found might be usable directly as a medical drug or indirectly as a compound for studying compounds that might be usable as a medical drug. Therefore, the objective of this invention is to identify such a molecule and use it as a medical drug or for the development of medical drugs.

### Presentation of the invention

The inventors of this invention studied diligently to find the desired protein by using genes expressed in the human brain, and as a result, they found the presence of a novel PGTH protein (prostaglandin transporter homologue), successfully isolated a pgth gene encoding the protein, and they arrived at this invention.

Specifically, this invention pertains to (a) a protein having the amino acid sequence described in sequence No. 1 or (b) a protein having an amino acid sequence with 1 to several amino acids deleted, substituted or added to the amino acid sequence of sequence No. 1, and having a prostaglandin transport activity.

Furthermore, this invention also pertains to (c) a gene comprising DNA described sequence No. 2 or (d) DNA which can be hybridized with the DNA of sequence No. 2 under stringent conditions and which encodes a protein having a prostaglandin transport activity.

The pgth gene of this invention can be isolated as a cDNA fragment containing the gene from a cDNA library of human brain origin. The cDNA library used by the inventors of this invention was prepared based on commercially available mRNA of human brain origin from the Clontech Co.

As a method for identifying the cDNA encoding a protein having a prostaglandin transport activity in the cDNA library described above, the method of Ohara, et al., (DNA Research 4: p 53, 1997) was used as an extensive cDNA library analysis method using a long-chain cDNA library. From a long-chain cDNA library of human brain origin prepared by the method of Ohara, et al., 25,000 recombinants are randomly selected, the 5' and 3' - base sequences of the cDNA from 15,000 clones were determined, and a clone showing homology to the gene encoding hPGT already reported from the 5' sequences of all the clones can be found by using a DNA analysis program (BLAST and FastA).

The presence of a region encoding the protein (ORF: open reading frame) in the base sequence can be confirmed by a conventional method using a computer program. After becoming confident of the presence of the desired gene in the cDNA sequence, the inventors of this invention found one ORF in the sequence by utilizing a computer, the gene was named pgth, and the protein encoded by the gene was named PGTH. The PGTH of the invention is a protein comprising a total of 709 amino acid residues and having a molecular weight of about 80 kd.

The invention pgth is a gene comprising 2130 bp shown in sequence No. 2. By using this pgth and conventional genetic recombination techniques using a suitable host vector system, it is possible to prepare a recombinant gene. As a suitable vector, there are plasmids of *E. coli* origin (such as pBR322, pUC118, etc.), of *Bacillus subtilis* origin, (such as pSH19, etc.) yeast origin plasmid (such as pUB110, pC194, etc.), bacteriophages, animal viruses such as retroviruses,

vaccinia virus, etc., etc. At the time of recombination, it is possible to add translation initiation and termination codons using suitable DNA adaptors. Furthermore, for gene expression, a suitable expression promoter is attached upstream of the gene. The promoter to be used is suitably selected depending on the host used. For example, if the host is *E. coli*, there are T7, lac, trp,  $\lambda$ PL promoters, etc.; if the host is a *Bacillus*, there are SPO promoters, etc.; if the host is a yeast, there are PHO5, GAP, ADH promoters, etc.; and if the host is an animal cell, there are SV40-origin, retrovirus promoters, etc.

Furthermore, the gene may be expressed as a fused protein with another protein (such as glutathione-S-transferase, protein A, etc.). In the case of a fused PGTH prepared by using such a method, a suitable protease (such as thrombin, etc.), may be used to cut out the protein.

As a host usable in the case of PGTH expression, there are various strains of *Escherichia coli*, various strains of *Bacillus subtilis*, various strains of the yeast *Saccharomyces cerevisiae* and animal cells such as COS-7, CHO cells, etc.

As a method for transforming a host cell using the above recombinant vector, a specific method conventionally used to transform the selected host cell is used.

Incidentally, in this invention, DNA which has a DNA sequence other than that shown in sequence No. 2 which can be hybridized with the DNA and encodes a protein having a prostaglandin transport activity, is also included in the scope of this invention.

Specifically, DNA which has a DNA sequence, the total length of the pgth sequence, partially changed due to various artificial treatments such as random mutations, introduction of site-specific mutations, or mutagen treatment, DNA fragment mutation, deletion ligation after scission with restriction enzymes, is also included in the scope of this invention in spite of having a DNA sequence different from that of sequence No. 2 as long as such a DNA variant can be hybridized with pgth under stringent conditions and encodes a protein having a prostaglandin transport activity.

The extent of the above DNA mutation is within the allowable range if the variant has 90% or higher homology with the DNA sequence of pgth. Furthermore, as an extent of hybridization with pgth, Southern hybridization with pgth may be carried out under conventional conditions, for example, in the case of probe labeling with a DIG DNA Labeling kit (Boehringer-Mannheim Cat. No. 1175033), hybridization conditions of a DIG Easy Hyb solution (Boehringer-Mannheim Cat. No. 1603558) at 32°C and washing of the membrane in a 5X SSC solution (containing 0.1% w/v SDS) at 50°C (1X SSC comprises 0.15M NaCl and 0.015M sodium citrate).

Furthermore, a protein encoded by the gene variant which is highly homologous to pgth as described above and has a prostaglandin transport activity is also included in the scope of this invention.

Specifically, a variant having one or more amino acids deleted, substituted or added to the amino acid sequence of PGTH is included in the scope of this invention as long as this variant is a protein having a prostaglandin transport activity.

The side chains of the amino acids, which are the constituent elements of proteins are respectively different with respect to hydrophobicity, electrical charge, size, etc., but several highly conservative relationships in the meaning of practically not affecting the three-dimensional structure (it is also called the steric structure) of proteins have been known from experiences or actual physicochemical observations. For example, for substitution of amino acid residues, there are glycine (Gly) and proline (Pro), Gly and alanine (Ala) or valine (Val), leucine (Leu) and isoleucine (Ile), glutamic acid (Glu) and glutamine (Gln), aspartic acid (Asp) and asparagine (Asn), cysteine (Cys) and threonine (Thr), Thr and serine (Ser) or Ala, lysine (Lys) and arginine (Arg), etc.

Therefore, any variant protein due to substitution, insertion, deletion, etc., in the amino acid sequence of the PGTH shown in sequence No. 1 can be said to be within the scope of this invention if the variation is a variation which conserves the three-dimensional structure of the PGTH, and the protein is a protein having a prostaglandin transport activity similar to PGTH. The allowable extent of this variation is 90% or higher homology with the amino acid sequence shown in sequence No. 1.

#### Industrial application field

The abnormal expression of pgth or functional failure of PGTH is presumed to be a critical disorder because PGTH has a prostaglandin transport activity, and consequently the normal prostaglandin production mechanism of the body is lost.

Therefore, PGTH itself is considered to be useful as a drug, and on the other hand, pgth or PGTH may be used for effectively studying or evaluating a substance having the same function as that of PGTH, a substance promoting or inhibiting its function, a substance promoting the expression of the gene, etc.

#### Best embodiment of the present invention

This invention is explained further in detail using application examples as follows, but this invention is certainly not limited to these application examples. Incidentally, unless specified, the experimental procedures used in the following application examples are those



described in standard experimental manuals such as Molecular Cloning, 2<sup>nd</sup> ed. (Cold Spring Harbor Laboratory Press, 1989), etc., and the operating manuals in commercially available kits, and they can be carried out under the conditions recommended for the respective commercially available products such as restriction enzymes, etc.

#### Application Example 1 Cloning of pgth

##### 1) Construction of a long chain cDNA library of human brain origin

An oligonucleotide (GACTAGTTCTAGATCGCGAGCGGCCGCCC(T)<sub>15</sub>) containing a NotI site was synthesized using a DNA synthesizer (ABI380B). It was used as a primer, and a double chain cDNA was synthesized using mRNA of human brain origin as a template and the SuperScript II reverse transcriptase kit (Gibco BRL). The ligation of the synthetic DNA was carried out with the cDNA and SalI site-containing adapter (Takara Shuzo), subsequently, NotI digestion was carried out, and cDNA fragments of 3 kb or larger were purified using electrophoresis with a 1% concentration of low-melting agarose.

After ligation of the purified cDNA fragments with a SalI-NotI restriction enzyme-treated pBluescriptIIISK+ plasmid, the recombinant plasmids were introduced into *E. coli* ElectroMax DH10B strain (Gibco BRL) using the electroporation method. Subsequently, 25,000 recombinants were randomly selected from the library, the recombinant DNAs were extracted, and the 5'- and 3'-base sequences of the cDNAs of 15,000 clones were determined. For the sequence determination, a PE Applied Biosystem Co., DNA sequencer (ABI PRISM377) and the reaction kit from the same company were used.

##### 2) Selection of clones containing the pgth sequence

The 5 sequences of all the clones determined in 1) were compared with the sequence of hPGT already reported using DNA analytical programs (BLAST and FastA), and as a result, a clone named HK07457 showed significant homology.

##### 3) DNA fragment base sequence determination

The base sequence determination was carried out using a PE Applied Biosystem Co. DNA sequencer and the dye primer method. The sequence was mostly determined using the shotgun method, and for a portion of the base sequence, an oligonucleotide was synthesized based on the base sequence already determined, and the primer walking method was used to determine the entire base sequences of the two chains. The entire base sequence of the cDNA of the clone is shown in sequence No. 3.

The cDNA contains an ORF encoding a protein (PGTH) comprising 709 residues. A termination codon was found to appear in the upstream region of a methionine residue, which was an initiation codon of the protein, with the same reading frame. Therefore, the amino acid sequence shown in sequence No. 3 was confirmed to be the only possibility as an amino acid sequence of the protein encoded by the cDNA fragment.

Figure 1 shows the amino acid homology between already reported hPGT and the PGTH of this invention. The two show high homology, especially, the position of the cysteine residue present at the C-terminal of PGTH is preserved, and the 77<sup>th</sup> residue glutamine, 561<sup>st</sup> residue arginine and 614<sup>th</sup> residue lysine of hPGT, which are amino acids especially important for the transport activity, are also preserved in PGTH.

### Application Example 2

Confirmation of protein expression by in vitro translation of pgth

The plasmid containing pgth prepared in Application Example 1 was treated with RNase A, subsequently, RNase A was removed using ADVAMAX beads (AGTC Co.), and in vitro translation was carried out using a TNT T7 coupled reticulocyte lysate system (Promega Co.) in the presence of (<sup>35</sup>S)-methionine. A portion of the reaction mixture was separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE), and the analysis carried out using BAS-2000 (Fuji Shashin Kogyo). As a result, the presence of a single band at about 80 kd was confirmed as shown in Figure 2.

### Application Example 3

Construction of animal cell expression vector

#### 1) Amplification of ORF-containing cDNA

An oligonucleotide (following sequence 1) having a sequence upstream from the initiation codon of the protein of sequence No. 3 and oligonucleotide (following sequence 2) having a sequence of a portion downstream from the termination codon of the protein and the reverse complementary strand chain were synthesized using a DNA synthesizer (ABI Co., Model 380B).

Sequence 1

5-CTGGAGCTCACTGCACTCCAGCAGTC-3

Sequence 2

5-AGCTCACACTCGGGAATCCTCTGGCTTC-3

The recombinant cDNA containing sequence No. 3 isolated in application example 1 was used as a template, the oligonucleotides of the sequences 1 and sequences 2 were used as a primer, and the following PCR procedures were carried out using a Takara LA PCR kit Ver. 2 and the PCR thermal cycler MP (Takara Shuzo).

cDNA	5 $\mu$ L (10 ng)
10X PCR buffer (containing 25 mM Mg <sup>++</sup> )	5 $\mu$ L
2.5 mM dNTP	8 $\mu$ L
10 $\mu$ M Sequence 1	2 $\mu$ L
10 $\mu$ M Sequence 2	2 $\mu$ L
Water	27.5 $\mu$ L
LA Taq polymerase	0.5 $\mu$ L
Total amount	50 $\mu$ L

The PCR cycle was carried out by holding at 94°C for 2 mn, carrying out the reaction at 98°C for 20 sec, cooling to 68°C at a rate of 1°C/2 sec, holding at 68°C for 3 min, at 72°C for 10 min, and repeating 30 times.

The above method was used to amplify a DNA fragment (about 2.2 kb) having a portion of sequence No. 3.

## 2) Subcloning to an animal cell expression vector

The DNA fragment amplified in 1) was fractionated by 1% agarose gel electrophoresis. After staining the gel with ethidium bromide, the gel containing the desired band observed under ultraviolet irradiation was cut out. The extraction of the DNA fragment from the agarose gel and purification were carried out using a GENECLAN II Kit (Bio101 Co.)

The extracted and purified DNA fragment was subcloned to animal cell expression vector pTARGET (Promega Co.) The ligation solution used was a Takara Ligation Kit Ver. 2 (Takara Shuzo), and the reaction was carried out with the following composition at 16°C for 1.5 h.

Extracted and purified DNA fragment	1 $\mu$ L (50 ng)
PTARGET	1 $\mu$ L (10 ng)
Water	3 $\mu$ L
<u>Ligation solution</u>	<u>5 <math>\mu</math>L</u>
Total	10 $\mu$ L

The reaction solution after the above reaction was used to transform the *E. coli* K12 strain DH5. The transformant was inoculated on an LB agar medium containing 50  $\mu$ g/mL of ampicillin (Amp), 40  $\mu$ g/mL of 5-bromo-4-chloro-3-indolyl- $\beta$ -D-galactoside (IPTG) [sic; isopropyl- $\beta$ -D-thiogalactopyranoside] and 100  $\mu$ M of isopropyl-b-D-thiogalactopyranoside

(X-gal) [sic; 5-bromo-4-chloro-3-indolyl- $\beta$ -D-galactopyranoside] \* and cultivated overnight at 37°C.

Each colony that developed on the above plate was inoculated in 10 mL of an LB liquid medium containing 50  $\mu$ g/mL of Amp, cultivation was carried out overnight at 37°C, the biomass was collected by centrifugation, and subsequently the recombinant DNA was purified using a QIAprep Spin Plasmid Miniprep Kit (Qiagen Co.) to obtain pTARGETpgth.

### 3) Determination of the base sequence of the inserted cDNA

The base sequence determination was carried out using a DNA sequencer (ABI Co., Model PRISM377) and the dye terminator method, and the whole base sequence of the two chains was determined using the primer walking method. The clone was found to contain all of the region between sequences 1 and 2 among sequence No. 3 confirming that the desired gene pTARGETpgth had been cloned.

### Application Example 4

#### Insertion into CHO<sub>k</sub>1 cells and stable transformant preparation

The recombinant DNA, pTARGETpgth, prepared in Application Example 2 has a CMV promoter upstream of pgth, and if it is inserted into an animal cell, the expression of pgth is possible.

CHO<sub>k</sub>1 cells were cultured in 60 mm diameter plastic Petri dishes. As the culture medium, Ham F-12 (Gibco, called growth medium, below) containing 10% fetal bovine serum (Dainippon Seiyaku), 50 U/mL of penicillin and 50  $\mu$ g/mL of streptomycin was used, and culture was carried out at 37°C in the presence of 5% CO<sub>2</sub>. When the cell density was 50%, LIPOFECTAMINE reagent (Gibco) containing pTARGETpgth prepared in Application Example 2 was added in a layer over the cells, incubated for 6 h, and, after replacement with the growth medium, culture was continued for 48 h. After dispersing the cells with trypsin, the cell suspension was placed in a 60 mm diameter plastic Petri dish, and culture was carried out for 24 h. After removing the culture medium, it was replaced by growth medium containing G418 (Gibco, final concentration of 500  $\mu$ g/mL). The G418 medium was changed every 3 days and culture continued for 2 weeks. When the cell colonies were observable with the naked eye, 3 colonies were isolated using stainless steel cups. As a control, only the pTARGET vector (Promega Co.) was inserted into CHO<sub>k</sub>1 cells by carrying out the same procedures as those described above to isolate a stable transformant.

---

\* [Editor's note: The compound names and abbreviations are so garbled in the original text that it is impossible to be certain whether it should be 40  $\mu$ g/mL IPTG and 100  $\mu$ M X-gal, or vice-versa.]

washed with a suitable buffer solution containing bovine serum albumin, and culture was continued for 20 min using a buffer solution containing ( $^3\text{H}$ )-labeled PGE<sub>2</sub> (Amersham Co.). After washing the cells, they were recovered, and the radioactivity taken up was measured. As a result, the prostaglandin transport activity of the CHO<sub>k</sub>1 cells with pgth inserted was statistically significantly higher than that of the CHO<sub>k</sub>1 cells with only the control vector inserted.

#### Application Example 6

Expression of pgth mRNA in human macrophages loaded with oxidized LDL

##### 1) Preparation of human macrophages loaded with oxidized LDL and normal monocyte cDNA

Normal monocyte cDNA was prepared using RNA prepared with Trizol (Gibco BRL Co.) from CD14-positive monocytes from human peripheral blood as a template and the SuperScript II reverse transcriptase kit (Gibco BRL). Human macrophages loaded with oxidized LDL were prepared by culturing normal monocytes in a RPMI-1640 medium (Dainippon Seiyaku) containing 20% AB serum and antibiotics for 14 days, adding human LDL oxidized with copper sulfate using conventional procedures (oxidized LDL) in the final concentration of 40  $\mu\text{mL}$  [sic; dimension incorrect] and continuing culture for 24 h. A method similar to that used for normal monocytes was used to prepare cDNA.

##### 2) Confirmation of pgth mRNA expression by the RT-PCR method

Oligonucleotides (following sequence 3) having a sequence contained in sequence No. 2 and oligonucleotides (following sequence 4) having the sequence of the reverse complementary strand were respectively synthesized using a DNA synthesizer (ABI Co., Model 380B).

##### Sequence 3

5-GCTCCTGCCCATTGGACGGCTTTAACC-3

##### Sequence 4

5-TCACACTCGGGAATCCTCTGGCTTC-3

The cDNA prepared in (1) was used as a template, the oligonucleotides with sequences 3 and 4 were used as primers, and the following PCR procedures were carried out using a Takara LA PCR kit Ver. 2 and the PCR thermal cycler MP (Takara Shuzo).

cDNA	2 $\mu\text{L}$ (40 ng)
10X PCR buffer (containing 25 mM $\text{Mg}^{++}$ )	1.5 $\mu\text{L}$
2.5 mM dNTP	2.4 $\mu\text{L}$

10 $\mu$ M Sequence 3	0.4 $\mu$ L
10 $\mu$ M Sequence 4	0.4 $\mu$ L
Water	10.15 $\mu$ L
LA Taq polymerase	0.15 $\mu$ L
Total amount	15 $\mu$ L

The PCR cycle was carried out by holding at 94°C for 5 min, carrying out the reaction at 94°C for 1 min, holding at 58°C for 1 min, furthermore at 72°C for 1 min, and repeating 30 times. The PCR reaction mixture was fractionated using 1% agarose gel electrophoresis. After staining the gel with ethidium bromide, the ultraviolet irradiation was carried out to detect an amplified band at about 500 bp. Similarly, the glyceraldehyde 3-phosphate dehydrogenase gene amplified primer (G3PDH, Clontech Co.) was used as the standard cDNA for PCR testing. As a result, the expression of pgth mRNA was strongly induced in the macrophages loaded with oxidized LDL, as shown in Figure 3.

Normal monocytes, macrophages loaded with oxidized LDL or equivalent cultured cells may be cultured with a test compound added, and subsequently the change in the PGTH mRNA may be measured by the method described above to screen any substance controlling PGTH mRNA expression.

#### Brief description of the figures

Figure 1 shows comparison of amino acid sequence homology between hPGT and the PGTH of this invention.

Figure 2 shows the results of SDS-PAGE of PGTH expressed using the in vitro translation method using pgth.

Figure 3 shows the results of detection of mRNA for the expression of pgth in human macrophages loaded with oxidized LDL using the RT-PCR method. In the figure o shows the results for human macrophages loaded with oxidized LDL, and m shows the results for normal human monocytes.

#### Claims

- (1) A protein of the following (a) or (b).
  - (a) Protein comprising the amino acid sequence of sequence No. 1
  - (b) Protein comprising an amino acid sequence with one or more amino acids deleted, substituted or added to the amino acid sequence of sequence No. 1, and, at the same time, having a prostaglandin transport activity.

- (2) DNA of the following (a) or (b).  
(a) DNA comprising the base sequence of sequence No. 2  
(b) DNA which can be hybridized with the DNA of sequence No. 2 under stringent conditions and at the same time, encodes a protein having a prostaglandin transport activity.

PGTH	WGPRIGPACEVPPQYDPDKETATMGCTENTPGCKASDPDQDYRPSVFHNIKLFVLCBSLLQLAQLAQLAISCYLKSSISIT	10	20	30	40	50	60	70
HPGT	MGLLPKLGYSQSGDTSISRAGRCARSAVFGNIKYFVLCQGLQLCQLLYSAFYKSSLLTT	10	20	30	40	50		
PGTH	VEKRFGLSSQTSGLLASFNEVGNTALIVFVSYFCGRVHRPRWIGYGAIVLVALAGLLMLPHFISEPVRYDNTSPE	80	90	100	110	120	130	140
HPGT	IEKRFGLSSSSSGLISSLSNEISNAILIIFVSYFCGRVHRPRLIGIGGLFLAAGAFILTLPHFELSEPYQYTLASTG	80	70	80	90	100	110	120
PGTH	DMPQDFXASLCLPT-ISAPASAPSNCGNCSSYTETQHLVSVVGIMFVAQTLLGVGGVPIQPFGISYIDDPAHNSNSP	160	170	180	190	200	210	220
HPGT	NNSR-LQAELCQXHWQDLPPSPKCHSTTONPKETS--SWGMLVVAQLLAGIGCTVPIQPFGISYVDDDFSEPSNSP	140	150	160	170	180	190	200
PGTH	LYLGILFAVTWECPGFLAGLGLSLMLRLVVDINQMPGCGISLTIKDPRRYVGAWLGLFLIAAGAVALAAIPYFFFFPK	230	240	250	260	270	280	290
HPGT	LYISILFAISYFCGPAFGYLLGSLMLQIFVDYGRYNTAAVNLVPGDPRWIGAWLGLLISSALLVLTISFPFFPPPR	210	220	230	240	250	260	270
PGTH	EMPKEKRELQFRKVLAVTDSAPKAGXDSPSIQSPGESTAKQDGLVQIAPNLTVIQPIKVFPRVLLQTLRHPFL	300	310	320	330	340	350	360
HPGT	AMP-----IGAXRAPATADEARKLEAKSRGS-----LVDFIKRFPFCIFLRLLMXNSLFY	290	300	310	320	330	340	350

Figure 1





## Replacement Sheet (Regulation 26)




Figure 2




Figure 3

## SEQUENCE LISTING

&lt;110&gt; TAISHO PHARMACEUTICAL CO., Ltd.

&lt;120&gt; Prostaglandin

&lt;130&gt; P487

&lt;150&gt; JP10-227723

&lt;151&gt; 1998-08-12

&lt;160&gt; 3

&lt;210&gt; 1

&lt;211&gt; 709

&lt;212&gt; PRT

&lt;213&gt; Homo sapience

&lt;400&gt; 1

```

Met Gly Pro Arg Ile Gly Pro Ala Gly Glu Val Pro Gln Val Pro
      5              10              15
Asp Lys Glu Thr Lys Ala Thr Met Gly Thr Glu Asn Thr Pro Gly
      20              25              30
Gly Lys Ala Ser Pro Asp Pro Gln Asp Val Arg Pro Ser Val Phe
      35              40              45
His Asn Ile Lys Leu Phe Val Leu Cys His Ser Leu Leu Gln Leu
      50              55              60
Ala Gln Leu Met Ile Ser Gly Tyr Leu Lys Ser Ser Ile Ser Thr
      65              70              75
Val Glu Lys Arg Phe Gly Leu Ser Ser Gln Thr Ser Gly Leu Leu
      80              85              90
Ala Ser Phe Asn Glu Val Gly Asn Thr Ala Leu Ile Val Phe Val
      95              100             105
Ser Tyr Phe Gly Ser Arg Val His Arg Pro Arg Met Ile Gly Tyr
      110             115             120
Gly Ala Ile Leu Val Ala Leu Ala Gly Leu Leu Met Thr Leu Pro
      125             130             135
His Phe Ile Ser Glu Pro Tyr Arg Tyr Asp Asn Thr Ser Pro Glu
      140             145             150
Asp Met Pro Gln Asp Phe Lys Ala Ser Leu Cys Leu Pro Thr Thr
      155             160             165
Ser Ala Pro Ala Ser Ala Pro Ser Asn Gly Asn Cys Ser Ser Tyr
      170             175             180
Thr Glu Thr Gln His Leu Ser Val Val Gly Ile Met Phe Val Ala
      185             190             195

```

Gln Thr Leu Leu Gly Val Gly Gly Val Pro Ile Gln Pro Phe Gly	200	205	210
Ile Ser Tyr Ile Asp Asp Phe Ala His Asn Ser Asn Ser Pro Leu	215	220	225
Tyr Leu Gly Ile Leu Phe Ala Val Thr Met Met Gly Pro Gly Leu	230	235	240
Ala Phe Gly Leu Gly Ser Leu Met Leu Arg Leu Tyr Val Asp Ile	245	250	255
Asn Gln Met Pro Glu Gly Gly Ile Ser Leu Thr Ile Lys Asp Pro	260	265	270
Arg Trp Val Gly Ala Trp Trp Leu Gly Phe Leu Ile Ala Ala Gly	275	280	285
Ala Val Ala Leu Ala Ala Ile Pro Tyr Phe Phe Phe Pro Lys Glu	290	295	300
Met Pro Lys Glu Lys Arg Glu Leu Gln Phe Arg Arg Lys Val Leu	305	310	315
Ala Val Thr Asp Ser Pro Ala Arg Lys Gly Lys Asp Ser Pro Ser	320	325	330
Lys Gln Ser Pro Gly Glu Ser Thr Lys Lys Gln Asp Gly Leu Val	335	340	345
Gln Ile Ala Pro Asn Leu Thr Val Ile Gln Phe Ile Lys Val Phe	350	355	360
Pro Arg Val Leu Leu Gln Thr Leu Arg His Pro Ile Phe Leu Leu	365	370	375
Val Val Leu Ser Gln Val Cys Leu Ser Ser Met Ala Ala Gly Met	380	385	390
Ala Thr Phe Leu Pro Lys Phe Leu Glu Arg Gln Phe Ser Ile Thr	395	400	405
Ala Ser Tyr Ala Asn Leu Leu Ile Gly Cys Leu Ser Phe Pro Ser	410	415	420
Val Ile Val Gly Ile Val Val Gly Gly Val Leu Val Lys Arg Leu	425	430	435
His Leu Gly Pro Val Gly Cys Gly Ala Leu Cys Leu Leu Gly Met	440	445	450
Leu Leu Cys Leu Phe Phe Ser Leu Pro Leu Phe Phe Ile Gly Cys	455	460	465
Ser Ser His Gln Ile Ala Gly Ile Thr His Gln Thr Ser Ala His	470	475	480
Pro Gly Leu Glu Leu Ser Pro Ser Cys Met Glu Ala Cys Ser Cys	485	490	495
Pro Leu Asp Gly Phe Asn Pro Val Cys Asp Pro Ser Thr Arg Val	500	505	510
Glu Tyr Ile Thr Pro Cys His Ala Gly Cys Ser Ser Trp Val Val	515	520	525
Gln Asp Ala Leu Asp Asn Ser Gln Val Phe Tyr Thr Asn Cys Ser	530	535	540
Cys Val Val Glu Gly Asn Pro Val Leu Ala Gly Ser Cys Asp Ser	545	550	555
Thr Cys Ser His Leu Val Val Pro Phe Leu Leu Leu Val Ser Leu	560	565	570

Gly	Ser	Ala	Leu	Ala	Cys	Leu	Thr	His	Thr	Pro	Ser	Phe	Met	Leu
				575					580					585
Ile	Leu	Arg	Gly	Val	Lys	Lys	Glu	Asp	Lys	Thr	Leu	Ala	Val	Gly
				590					595					600
Ile	Gln	Phe	Met	Phe	Leu	Arg	Ile	Leu	Ala	Trp	Met	Pro	Ser	Pro
				605					610					615
Val	Ile	His	Gly	Ser	Ala	Ile	Asp	Thr	Thr	Cys	Val	His	Trp	Ala
				620					625					630
Leu	Ser	Cys	Gly	Arg	Arg	Ala	Val	Cys	Arg	Tyr	Tyr	Asn	Asn	Asp
				635					640					645
Leu	Leu	Arg	Asn	Arg	Phe	Ile	Gly	Leu	Gln	Phe	Phe	Phe	Lys	Thr
				650					655					660
Gly	Ser	Val	Ile	Cys	Phe	Ala	Leu	Val	Leu	Ala	Val	Leu	Arg	Gln
				665					670					675
Gln	Asp	Lys	Glu	Ala	Arg	Thr	Lys	Glu	Ser	Arg	Ser	Ser	Pro	Ala
				680					685					690
Val	Glu	Gln	Gln	Leu	Leu	Val	Ser	Gly	Pro	Gly	Lys	Lys	Pro	Glu
				695					700					705
Asp	Ser	Arg	Val											
				709										

<210> 2  
 <211> 2130  
 <212> ONA  
 <213> Homo sapiens

<400> 2

10	20	30	40	50	60	
algggaccca	ggatagggcc	agcgggigag	giacccagg	laccagacaa	ggaaaccaa	60
gccacaalgg	gcacagaaaa	cacaccigga	ggcaaagcca	gccagaccc	icaggacgig	120
cggccaagig	iglitccataa	caicaagcig	ticgticig	gccacagcci	gcigcagcig	180
gcgcagctca	lgaicccgg	ciacctaaag	agctccatci	ccacagigga	gaagcgcttc	240
ggctcticca	gccagacgic	ggggcigcig	gccicctica	acgaggiggg	gaacacagcc	300
ltagatigig	ltagagcia	lilggcagc	cgggigcacc	gaccccgaa	galiggctai	360
ggggctatcc	lilggccci	ggcgggccc	cicagacic	lcccgacii	calctcgag	420
ccataccgci	acgacaacac	cagcccigag	gataigccac	aggaclicaa	ggctlccclg	480
lgcctgccc	caatcicggc	cccagccicg	gccccctcca	alggcaacig	cicaagctac	540
acagaaaccc	agcatctgag	lglgggggg	atcagcttcg	lggcacagac	ccigcigggc	600

giggcgggg lgcccalica gcccllggc alclccclaca lcgalgacil lgcccaaac 660  
agcaacigc cccclaccl cgggaltclg lllgcagiga ccalgalgg gccaggccig 720  
gccllgggc lgggcagcc calgcigcgc clllaiglg acallaacca galgccagaa 780  
gglgglaica gccigaccal aaaggacccc cgalgggigg glgclggig gclgggllc 840  
clcalcglc cgggigcagl ggccciggl gccalcccc alclclcll ccccaaggaa 900  
algcccaagg aaaaacgiga gcllcaglll cggcgaaagg lcllagcagl cacagacica 960  
cclgccagga agggcaagga clclcccccl aagcagagcc clggggaglc caggaagaag 1020  
caggalggcc laglccagal lgcaccaaac clgacigiga lccagllcal laaaglclic 1080  
cccaggglc lgcigcagac cclacgccac cccalclic lgciggggl cclglccag 1140  
glalgcilgl calccalggc lgcgggcatg gccaccllc lgcccaagll cclggagcgc 1200  
cagllilcca lcaagcccl clacgccaac clgcicalc glgccclic clccccicg 1260  
glcalcglg gcalcglgl gggiggcglc clggtaagc ggclccaccl ggcccclg 1320  
ggalgcggl cccllggcl glggggal clgcllgcc clclclcag cclggcglc 1380  
llclllaicg glgclccag ccaccagall gcgggcalca cacaccagac caglgcccac 1440  
cclggcglg agclgcllc aagclgcal gagggclgl cclggccall ggacggcll 1500  
aaccclgcl gcgacccag cclcgllg gaalacalca caccclgca cgcaggclg 1560  
lcaagclgg lggccagga lgcclggac aacagccagg llclclacac caaclgcagc 1620  
lgcglgggg agggcaacc cglgclggca ggalcclgc aclcaacgl cagccalcig 1680  
gigglgcccl lcclgclcl gglcagccg ggclggccc lggcclgcl caccacaca 1740  
cccclclca lgcclaccl aagaggaglg aagaaagaag acaagacil ggclgtgggc 1800  
alccagllca lglccigag galllggcc lggalggcca gcccglgal ccacggcagc 1860  
gccalcgaca ccacciggl gcclgggcc clgagclgl ggcglcagc lglclgclg 1920  
lcllacaala algacclgl ccgaaaccgg lcalcggcc lccagllcl clcaaaaaca 1980  
ggllcigla lclgcllcc cllagllllg glglcciga ggcagcagga caaagggca 2040  
aggaccaaag agagcagalc cagccclgcc glagagcagc aalglcagl glcggggcca 2100

gggaagaagc cagaggatc cagagtgga

2130

<210> 3  
 <211> 4083  
 <212> DNA  
 <213> Homo sapiens

&lt;400&gt; 3

aagtagacca gggagacaaa cacitggaga tacitggggc tgaglitag caagactccc 60  
 taacctigti caggacaagi ctagticci gtagggccca agaagaacig accccgigtc 120  
 tggagctccc accgltatig calccctgci ggggctacc tgcctgctc tccaggagcc 180  
 ccagagaaga ttgcccctc cccccctgci aagctccagg tccagagat gaattagggg 240  
 caggagctca ctgcactcca gcagtc 266  
 atg gga ccc agg ala ggg cca gcg ggt gag gla ccc cag gla cca 311  
 Met Gly Pro Arg Ile Gly Pro Ala Gly Glu Val Pro Gln Val Pro  
 5 10 15  
 gac aag gaa acc aaa gcc aca atg ggc aca gaa aac aca cct gga 356  
 Asp Lys Glu Thr Lys Ala Thr Met Gly Thr Glu Asn Thr Pro Gly  
 20 25 30  
 ggc aaa gcc agc cca gac cct cag gac gtc cgg cca agt gtc ttc 401  
 Gly Lys Ala Ser Pro Asp Pro Gln Asp Val Arg Pro Ser Val Phe  
 35 40 45  
 cat aac atc aag ctg ttc gtt ctg tgc cac agc ctg ctg cag ctg 446  
 His Asn Ile Lys Leu Phe Val Leu Cys His Ser Leu Leu Gln Leu  
 50 55 60  
 gcg cag ctg atg atc tcc ggc tac cta aag agc tcc atc tcc aca 491  
 Ala Gln Leu Met Ile Ser Gly Tyr Leu Lys Ser Ser Ile Ser Thr  
 65 70 75  
 gtc gag aag cgc ttc ggc ctg tcc agc cag acg tgc ggg ctg ctg 536  
 Val Glu Lys Arg Phe Gly Leu Ser Ser Gln Thr Ser Gly Leu Leu  
 80 85 90  
 gcc tcc ttc aac gag gtc ggg aac aca gcc ttg att gtc ttt gtc 581  
 Ala Ser Phe Asn Glu Val Gly Asn Thr Ala Leu Ile Val Phe Val  
 95 100 105  
 agc tat ttt ggc agc cgg gtc cac cga ccc cga atg att ggc tat 626  
 Ser Tyr Phe Gly Ser Arg Val His Arg Pro Arg Met Ile Gly Tyr  
 110 115 120  
 ggg gct atc ctt gtc gcc ctg gcg ggc ctg ctg atg act ctg ccg 671  
 Gly Ala Ile Leu Val Ala Leu Ala Gly Leu Leu Met Thr Leu Pro  
 125 130 135  
 cac ttc atc tgc gag cca tac cgc tac gac aac acc agc cct gag 716  
 His Phe Ile Ser Glu Pro Tyr Arg Tyr Asp Asn Thr Ser Pro Glu  
 140 145 150

gat atg cca cag gac ttc aag gcl lcc ctg tgc ctg ccc aca acc	761
Asp Met Pro Gln Asp Phe Lys Ala Ser Leu Cys Leu Pro Thr Thr	
155 160 165	
tcg gcc cca gcc tcg gcc ccc tcc aat ggc aac tgc tca agc tac	806
Ser Ala Pro Ala Ser Ala Pro Ser Asn Gly Asu Cys Ser Ser Tyr	
170 175 180	
aca gaa acc cag cal ctg agt glg glg ggg aic aig ttc glg gca	851
Thr Glu Thr Gln His Leu Ser Val Val Gly Ile Met Phe Val Ala	
185 190 195	
cag acc ctg ctg ggc glg ggc ggg glg ccc att cag ccc ttt ggc	896
Gln Thr Leu Leu Gly Val Gly Gly Val Pro Ile Gln Pro Phe Gly	
200 205 210	
atc lcc tac aic gal gac ttt gcc cac aac agc aac tcg ccc ctg	941
Ile Ser Tyr Ile Asp Asp Phe Ala His Asn Ser Asn Ser Pro Leu	
215 220 225	
tac ctg ggg aic ctg ttt gca glg acc aig atg ggg cca ggc ctg	986
Tyr Leu Gly Ile Leu Phe Ala Val Thr Met Met Gly Pro Gly Leu	
230 235 240	
gcc ttt ggg ctg ggc agc ctg atg ctg cgc ctt tat gtg gac att	1031
Ala Phe Gly Leu Gly Ser Leu Met Leu Arg Leu Tyr Val Asp Ile	
245 250 255	
aac cag atg cca gaa ggt ggt aic agc ctg acc ata aag gac ccc	1076
Asn Glu Met Pro Glu Gly Gly Ile Ser Leu Thr Ile Lys Asp Pro	
260 265 270	
cga tgg gtg ggt gcc tgg tgg ctg ggt ttc ctg atc gcl gcc ggt	1121
Arg Trp Val Gly Ala Trp Trp Leu Gly Phe Leu Ile Ala Ala Gly	
275 280 285	
gca glg gcc ctg gcl gcc atc ccc tac ttc ttc ttc ccc aag gaa	1166
Ala Val Ala Leu Ala Ala Ile Pro Tyr Phe Phe Phe Pro Lys Glu	
290 295 300	
alg ccc aag gaa aaa cgt gag ctt cag ttt cgg cga aag gtc tta	1211
Met Pro Lys Glu Lys Arg Glu Leu Gln Phe Arg Arg Lys Val Leu	
305 310 315	
gca gtc aca gac tca cct gcc agg aag ggc aag gac tct ccc tct	1256
Ala Val Thr Asp Ser Pro Ala Arg Lys Gly Lys Asp Ser Pro Ser	
320 325 330	
aag cag agc cct ggg gag tcc acg aag aag cag gal ggc cta gtc	1301
Lys Gln Ser Pro Gly Glu Ser Thr Lys Lys Gln Asp Gly Leu Val	
335 340 345	
cag att gca cca aac ctg act gtg atc cag ttc att aaa gtc ttc	1346
Gln Ile Ala Pro Asn Leu Thr Val Ile Gln Phe Ile Lys Val Phe	
350 355 360	
ccc agg gtg ctg ctg cag acc cta cgc cac ccc atc ttc ctg ctg	1391
Pro Arg Val Leu Leu Gln Thr Leu Arg His Pro Ile Phe Leu Leu	
365 370 375	
gtg glc ctg tcc cag gta tgc ttg tca lcc alg gcl gcg ggc atg	1436
Val Val Leu Ser Gln Val Cys Leu Ser Ser Met Ala Ala Gly Met	
380 385 390	
gcc acc ttc ctg ccc aag ttc ctg gag cgc cag ttt tcc atc aca	1481
Ala Thr Phe Leu Pro Lys Phe Leu Glu Arg Gln Phe Ser Ile Thr	

395	400	405	
gcc tcc tac gcc aac ctc ctc alc ggc tgc ctc tcc ttc cct tgc			1526
Ala Ser Tyr Ala Asn Lcu Leu lle Gly Cys Leu Ser Phe Pro Ser			
410	415	420	
gtc atc gtc ggc alc gtc gtc ggc ggc gtc ctc gtc aag cgg ctc			1571
Val lle Val Gly lle Val Val Gly Gly Val Leu Val Lys Arg Leu			
425	430	435	
cac ctc ggc cct gtc gga tgc ggc gcc ctt tgc ctc ctc ggc aig			1616
His Lcu Gly Pro Val Gly Cys Gly Ala Leu Cys Leu Lcu Gly Met			
440	445	450	
ctc ctc tgc ctc ttc ttc agc ctc cgc ctc ttc ttt atc ggc tgc			1661
Leu Leu Cys Leu Phe Phe Ser Leu Pro Leu Phe Phe lle Gly Cys			
455	460	465	
lcc agc cac cag att ggc ggc alc aca cac cag acc agt gcc cac			1706
Ser Ser His Gln lle Ala Gly lle Thr His Gln Thr Ser Ala His			
470	475	480	
cct ggc ctc gag ctc tct cca agc tgc atg gag gcc tgc tcc tgc			1751
Pro Gly Leu Glu Leu Ser Pro Ser Cys Met Glu Ala Cys Ser Cys			
485	490	495	
cca ttg gac ggc ttt aac cct gtc tgc gac ccc agc act cgt gtc			1796
Pro Lcu Asp Gly Phe Asn Pro Val Cys Asp Pro Ser Thr Arg Val			
500	505	510	
gaa tac atc aca ccc tgc cac gca ggc tgc tca agc tgg gtc gtc			1841
Glu Tyr lle Thr Pro Cys His Ala Gly Cys Ser Ser Trp Val Val			
515	520	525	
cag gat gct ctc gac aac agc cag gtt ttc tac acc aac tgc agc			1886
Gln Asp Ala Lcu Asp Asn Ser Gln Val Phe Tyr Thr Asn Cys Ser			
530	535	540	
tgc gtc gtc gag ggc aac ccc gtc ctc gca gga tcc tgc gac tca			1931
Cys Val Val Glu Gly Asn Pro Val Leu Ala Gly Ser Cys Asp Ser			
545	550	555	
acg tgc agc cat ctc gtc gtc ccc ttc ctc ctc ctc gtc agc ctc			1976
Thr Cys Ser His Leu Val Val Pro Phe Leu Leu Leu Val Ser Leu			
560	565	570	
ggc tgc gcc ctc gcc tgc ctc acc cac aca ccc tcc ttc atg ctc			2021
Gly Ser Ala Leu Ala Cys Leu Thr His Thr Pro Ser Phe Met Leu			
575	580	585	
atc cta aga gga gtc aag aaa gaa gac aag act ttg gct gtc ggc			2066
lle Leu Arg Gly Val Lys Lys Glu Asp Lys Thr Lcu Ala Val Gly			
590	595	600	
atc cag ttc atg ttc ctc agc att ttg gcc tgg atg ccc agc ccc			2111
lle Gln Phe Met Phe Leu Arg lle Leu Ala Trp Met Pro Ser Pro			
605	610	615	
gtc atc cac ggc agc gcc atc gac acc acc tgc gtc cac tgg gcc			2156
Val lle His Gly Ser Ala lle Asp Thr Thr Cys Val His Trp Ala			
620	625	630	
ctc agc tgc ggc cgt cga gct gtc tgc cgc tac tac aat aat gac			2201
Leu Ser Cys Gly Arg Arg Ala Val Cys Arg Tyr Tyr Asn Asn Asp			
635	640	645	
ctc ctc cga aac cgc ttc atc ggc ctc cag ttc ttc ttc aaa aca			2246



Leu	Leu	Arg	Asn	Arg	Phe	Ile	Gly	Leu	Gln	Phe	Phe	Phe	Lys	Thr			
				650					655					660			
ggi	lcl	gig	alc	lge	lil	gcc	lla	gli	lig	gcl	gic	cig	agg	cag		2291	
Gly	Ser	Val	Ile	Cys	Phe	Ala	Leu	Val	Leu	Ala	Val	Leu	Arg	Gln			
				665					670					675			
cag	gac	aaa	gag	gca	agg	acc	aaa	gag	agc	aga	icc	agc	ccl	gcc		2336	
Gln	Asp	Lys	Glu	Ala	Arg	Thr	Lys	Glu	Ser	Arg	Ser	Ser	Pro	Ala			
				680					685					690			
gla	gag	cag	caa	lig	cla	gig	icg	ggg	cca	ggg	aag	aag	cca	gag		2381	
Val	Glu	Gln	Gln	Leu	Leu	Val	Ser	Gly	Pro	Gly	Lys	Lys	Pro	Glu			
				695					700					705			
gal	icc	cga	gig	lga												2396	
Asp	Ser	Arg	Val														
				709													

gcigicligg ggccccaccl ggccaagagi agcagccaca gcagiaccic ccligagicc 2456

lilgcccag aillgggigic aagagccclg lglilccalc lggclccicc aclaaaligc 2516

lgilgacil caggcaagac allgalccic lclcagccil lgciligclag lcigaaccaa 2576

agagliglil ggccalligc lglilggcc allcclggag caagagggic lcllccicc 2636

lccccagc cagccagcig lcciggggcc aggciliccl ggglggaaag aaglalacci 2696

lccccgggg ccclaggata gcaaaglgag ccalaglggg ccaggcigcc clccalgcig 2756

ggccccagcc caggliclca clcgccigga lcacclilcl lragccclag ccclclccig 2816

lcagglagga algaacilgc cagccclcag gclcglicag clalagccal clglgcggic 2876

aggglacaci cagclclcccl ccccaacicc agcagcccll aagaaglgic cclilggcgc 2936

cccclggagg cagagccclg agclggaccc lggglagaci cccacaggga ggacggagci 2996

ggccicagga glgggacacc cagccclggc agggcclica agaggccclg glgggggccc 3056

caggaalcccl lagclgaagc gggggagalc acclccalc lcaggaaall clagccclig 3116

ccclcaggga gccacgglig agggigagcc ccaacaccig ccllagggcc clgggigggc 3176

aagclgggc cclgggclag ggaggagac lcaggccac acilgggial lllclaaall 3236

cagacaaaca cacalcagc gcgcaciac lgalcciac acaligccaa galilcacac 3296

alglgaccag gggccaccaa aglccclgic accilgiga claggalcccl aallclclia 3356

lllclccig ggigcciggg lcigilclic clggggcagl glggalaalg lllagllclg 3416

lgacacigll llllggggcl ggcacciggl lclccgalgc clgggciggl gicaggccca 3476

ggaciglagi gcigggagca gtaaagctca gcicigigia algagigaig cialggcilig 3536  
cicgigicli algalccaal ccilicclac alcageccil gilligilli alggciagtc 3596  
llaiclggcc iggtlaillc cllgcgggga ggagagggtt tgciaatcig cleccagccc 3656  
aacctallac caccceaccl cgcigggacc lacigcicgg gaggcagcag acaggagacc 3716  
accagcagig gclicciggc ccigicicgg gggigggggg aagciggggg cacaiglggc 3776  
ccligccile lgagcagcic ccaglgccag ggclligaga cilicccaca tgalaaaaga 3836  
aaagggaggi acagaagtic caallicccl lllalillgc tggllggial ciglaaaigt 3896  
llaataaata tcigagcag laclalcaa cgccaagaal ticaaagict ccliccaaca 3956  
talgaggccl ltaggaigll laaliliccl calcciccl glticccagg lillgcaggg 4016  
aaaaaaagtc iggaattata galacagccl altaltaaat ligitcligc ataaaaaaaa 4076  
aaaaaaa 4083

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/JPO/04352

## A. CLASSIFICATION OF SUBJECT MATTER

Int.Cl.<sup>6</sup> C07K 14/47, C12N 15/12//C12N 5/10, C12P 21/02,  
(C12P 21/02, C12R 1:91)

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Int.Cl.<sup>6</sup> C07K 14/47, C12N 15/12, C12N 5/10, C12P 21/02,

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
SwissProt/PIR/GeneSeq, Genbank/EMBL/DDBJ/GeneSeq,  
WPI (DIALOG), BIOSIS (DIALOG)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US, 5792851, A (Albert Einstein College of Medicine of Yeshiva University, a Division of Yeshiva University) 11 August, 1998 (11.08.98) (Family: none)	1, 2
Y	Journal of Clinical Investigation, Vol.98, no.5 (1996) Lu Run, et al., "Cloning, in vitro expression, and tissue distribution of a human prostaglandin transporter cDNA (hPGT)" see p.1142-1149, (1996)	1, 2
Y	Biochemical and Biophysical Research Communications, Vol.246, No.3, (May 29, 1998), Lu Run, et al., "Molecular cloning of the gene for human prostaglandin transporter hPGT: Gene organization, promoter activity and chromosomal localization", see p.805-812,	1, 2

☒ Further documents are listed in the continuation of Box C.

☐ See patent family annex.

\* Special categories of cited documents:  
"A" document defining the general state of the art which is not considered to be of particular relevance  
"E" earlier document but published on or after the international filing date  
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)  
"O" document referring to an oral disclosure, use, exhibition or other means  
"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention  
"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone  
"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art  
"&" document member of the same patent family

Date of the actual completion of the international search  
09 November, 1999 (09.11.99)

Date of mailing of the international search report  
24 November, 1999 (24.11.99)

Name and mailing address of the ISA/  
Japanese Patent Office

Authorized officer

Facsimile No.

Telephone No.

## INTERNATIONAL SEARCH REPORT

International Application No.

PCT/JP99/04352

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	Science, vol.268, No.5212, (1995), Kanai Naoaki et al., "Identification and Characterization of a prostaglandin transporter ", see p.866-869,	1-2